Pharvaris gains after genetic disorder drug meets late-stage trial goal
08/09/2026 12:55
BUZZ-Pharvaris gains after genetic disorder drug meets late-stage trial goal ** Shares of oral therapy developer Pharvaris PHVS.O rise 15.9% to $40.86 premarket
** Co says its experimental drug deucrictibant met the main goal of a late-stage trial in patients with hereditary angioedema, a rare genetic disorder that causes repeated swelling attacks
** Drug cut monthly attack rate by 83% vs placebo, and by 87% in the two most common types of the disorder
** Trial included 85 adolescents and adults; no treatment-related serious side effects were reported
** Co plans to seek U.S. approval for the preventive treatment in H1 2027
** As of last close, PHVS up 27% YTD
(Reporting by Kunal Das in Bengaluru)
Recent news on Pharvaris
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Pharvaris gains after genetic disorder drug meets late-stage trial goal